


Neuroprotective Strategies in Neurodegenerative Diseases Group




Publications: **10** Impact Factor: **62.421** QI: **9**

Research Activity

PUBLICATIONS

- Egea J, Fabregat I, Frapart YM, Ghezzi P, Gorlach A, Kietzmann T, Kubaichuk K, Knaus UG, López MG, Olaso-González G, Petry A, Schulz R, Vinal J, Winyard P, Abbas K, Ademowo OS, Afonso CB, Andreadou I, Antelmann H, Antunes F, Aslan M, Bachschmid MM, Barbosa RM, Belousov V, Berndt C, Bernlohr D, Bertran E, Bindoli A, Bottari SP, Brito PM, Carrara G, Casas AI, Chatzi A, Chondrogiani N, Conrad M, Cooke MS, Costa JG, Cuadrado A, Dang PMC, De Smet B, Butuner BD, Dias IHK, Dunn JD, Edson AJ, El Assar M, El-Benna J, Ferdinandy P, Fernandes AS, Fladmark KE, Forstermann U, Giniatullin R, Giricz Z, Gorbe A, Griffiths H, Hampl V, Hanf A, Herget J, Hernansanz-Agustin P, Hillion M, Huang JJ, Ilikay S, Jansen-Durr P, Jaquet V, Joles JA, Kalyanaraman B, Kaminsky D, Karbaschi M, Kleanthous M, Klotz LO, Korac B, Korkmaz KS, Koziel R, Kracun D, Krause KH, Kren V, Krieg T, Laranjinha J, Lazou A, Li HG, Martínez-Ruiz A, Matsui R, McBean GJ, Meredith SP, Messens J, Miguel V, Mikhed Y, Milisav I, Milkovic L, Miranda-Vizuete A, Mojovic M, Monsalve M, Mouthuy PA, Mulvey J, Munzel T, Muzykantov V, Nguyen ITN, Oelze M, Oliveira NG, Palmeira CM, Papaevgeniou N, Pavicevic A, Pedre B, Peyrot F, Phylactides M, Pircalabioru GG, Pitt AR, Poulsen HE, Prieto I, Rigobello MP, Robledinos-Antón N, Rodríguez-Mañas L, Rolo AP, Rousset F, Ruskovska T, Saraiva N, Sasson S, Schroder K, Semen K, Seredenina T, Shakirzyanova A, Smith GL, Soldati T, Sousa BC, Spickett CM, Stancic A, Stasia MJ, Steinbrenner H, Stepanic V, Steven S, Tokatlidis K, Tuncay E, Turan B, Ursini F, Vacek J, Vajnerova O, Valentova K, Van Breusegem F, Varisli L, Veal EA, Yalcin AS, Yelisyeyeva O, Zarkovic N, Zatloukalova M, Zielonka J, Touyz RM, Papapetropoulos A, Grune T, Lamas S, Schmidt HHHW, Di Lisa F, Daiber A. European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BMI203 (EU-ROS). *Redox Biol.* 2017; 13: 94-162. Review. IF: 7.126; Q1
- Escoll M, Gargini R, Cuadrado A, Antón IM, Wandosell F. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ. *Oncogene.* 2017; 36(25): 3515-27. Article. IF: 6.854; Q1
- Gameiro I, Michalska P, Tenti G, Cores A, Buendía I, Rojo AI, Georgakopoulos ND, Hernández-Guijo JM, Ramos MT, Wells G, López MG, Cuadrado A, Menéndez JC, León R. Discovery of the first dual GSK3 beta inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease. *Sci Rep-Uk.* 2017; 7: 45701. Article. IF: 4.122; Q1
- Navarro E, González-Lafuente L, Pérez-Liebana I, Buendía I, López-Bernardo E, Sánchez-Ramos C, Prieto I, Cuadrado A, Sastrategui J, Cadenas S, Monsalve M, López MG. Heme-oxygenase 1 and PCG-1 alpha regulate mitochondrial biogenesis via microglial activation of alpha7 nicotinic acetylcholine receptors using PNU282987. *Antioxid Redox Sign.* 2017; 27(2): 93-105. Article. IF: 6.53; D1
- Nayernia Z, Colaianna M, Robledinos-Antón N, Gutzwiller E, Sloan-Bena F, Stathaki E, Hibaoui Y, Cuadrado A, Hescheler J, Stasia MJ, Saric T, Jaquet V, Krause KH. Decreased neural precursor cell pool in NADPH oxidase 2-deficiency: From mouse brain to neural differentiation of patient derived iPSC. *Redox Biol.* 2017; 13: 82-93. Article. IF: 7.126; Q1
- Pajares M, Cuadrado A, Rojo AI. Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. *Redox Biol.* 2017; 11: 543-53. Review. IF: 7.126; Q1
- Robledinos-Antón N, Rojo AI, Ferreiro E, Núñez A, Krause KH, Jaquet V, Cuadrado A. Transcription factor NRF2 controls the fate of neural stem cells in the subgranular zone of the hippo-

Neuroscience Area



campus. Redox Biol. 2017; 13: 393-401. Article. IF: 7.126; Q1

- Rojo AI, Pajares M, Rada P, Núñez A, Nevado-Holgado AJ, Killik R, Van Leuven F, Ribe E, Lovestone S, Yamamoto M, Cuadrado A. NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. Redox Biol. 2017; 13: 444-51. Article. IF: 7.126; Q1
- Tobón-Velasco JC, Limón-Pacheco JH, Orozco-Ibarra M, Macías-Silva M, Vázquez-Victorio G, Cuevas E, Ali SF, Cuadrado A, Pedraza-Chaverri J, Santamaría A. 6-OHDA-induced apoptosis and mitochondrial dysfunction are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-kappa B factors. Toxicology. 2017; 390: 167. Article. IF: 3.265; Q2
- Tobón-Velasco JC, Vázquez-Victorio G, Macías-Silva M, Cuevas E, Ali SF, Maldonado PD, González-Trujano ME, Cuadrado A, Pedraza-Chaverri J, Santamaría A. S-Allyl cysteine protects against 6-hydroxydopamine-induced neurotoxicity in the rat striatum: involvement of Nrf2 transcription factor activation and modulation of signaling kinase cascades. Free Radical Bio Med. 2017; 104: 382. Article. IF: 6.02; Q1

PUBLIC PROJECTS

Cuadrado Pastor A. Red de investigación en NRF2 como nodo del patogenosoma (SAF2015-71304-REDT). MINECO. 2015-2017.

Management centre: UAM

Martínez Valverde A. Inflammation associated with cronic metabolic damage in diabetes mellitus and its complications (SAF2015-65267-R). MINECO. 2016-2018.

Management centre: CSIC

PRIVATE PROJECTS

Cuadrado Pastor A. Targeting NRF2 with SFX-01 to modify Parkinson's disease progression in the AAV6-A-synuclein mouse model. Evgen. 2016-Ongoing.

Management centre: UAM

Martínez Valverde A. Desarrollo de mecanismo de acción del glicinato de metformina en un modelo de hepatocitos. Laboratorios Silanes. 2015-2017.

Management centre: CSIC

Martínez Valverde A. Colaboración para el fomento de la investigación desarrollada en el grupo IdiPAZ Estrategias Neuroprotectoras en Enfermedades Neurodegenerativas. FIBHULP. 2013-Ongoing.

Management centre: FIBHULP

INTERNATIONAL PROJECTS

Cuadrado Pastor A. Aproximación terapéutica avanzada en cáncer combinando terapia fotodinámica y nanopartículas (PCIN-2016-071). MINECO-EU. 2016-2018.

Management centre: UAM

Cuadrado Pastor A. Knowledge transfer in redox biology for developing advanced molecular tools in neurodegenerative diseases - focus on the signature of NRF2 transcription factor in diagnosis and therapy (P_37_732). EU. 2016-2020.

Management centre: Víctor Babes National Institute of Pathology (Bucharest)

PATENTS AND TRADEMARKS

Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October 15.